From 2024 to 2031, the global Peptide-Based Gastrointestinal Disorders Therapeutics Market is anticipated to grow at a compound annual growth rate (CAGR) of XX.X%. The market is expected to reach a value of USD XX.X billion by 2024 and is projected to grow to USD XX.X billion by 2031.
Manufacturers play a significant role in a wide range of industries, influencing customer preferences, supply chains, and economic growth. From consumer electronics to pharmaceuticals and auto parts, manufacturers are key players in the creation and distribution of goods. Their efficiency, innovation, and quality standards directly impact customer satisfaction and market competitiveness. Manufacturers also shape market trends, drive growth, advance technology, create jobs, and contribute to the development of the sector as a whole.
For more insights into the Market, Request a Sample of this Report – https://www.factmr.com/connectus/sample?flag=S&rep_id=4646
A peptide is a biological, naturally occurring or synthetic form of amino acid monomers. Peptides can be used to treat a variety of gastrointestinal problems, which mostly affect the gastrointestinal tract, large intestine, small intestine, stomach, esophagus, and rectum.
Peptides are regarded as an efficient treatment agent for gastrointestinal disorders. Due to their remarkable preclinical findings, a slew of new peptide-based gastrointestinal disease treatments are expected to hit the market soon.
North America to Dominate the Global Peptide-Based Gastrointestinal Disorders Therapeutics Market
North America is anticipated to maintain its leading position in the global peptide-based gastrointestinal disorders therapeutics market, driven by increasing patient awareness and the rapid adoption of peptide-based treatments for various conditions.
The regional market is forecasted to grow at an impressive CAGR of 13.9% during the projection period.
Among drugs, the linaclotide segment is expected to remain dominant through 2022, currently holding over two-thirds of the market share in terms of revenue. By the end of the forecast period, this segment is projected to surpass a market valuation of US$ 466 million.
Competition Tracking
- Shire plc
- Ironwood Pharmaceuticals, Inc.
- Astellas Pharma Inc.
- Allergan plc
- Accredo Health Group, Inc.
These are the key market players featured in Fact.MR’s report. Most of these companies are focusing their investments on expanding their product portfolios.
This strategy is expected to drive the development and launch of more effective peptide-based therapeutic drugs for treating gastrointestinal disorders.
Market Taxonomy
By Drug:
- Teduglutide
- Linaclotide
By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Contact:
Comments
0 comment